Cadila Healthcare - Vaccine Approval Adds A New Dimension To Domestic Business: Motilal Oswal
BQ Blue’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BloombergQuint’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Motilal Oswal Report
Cadila Healthcare Ltd. has received emergency use authorisation for its plasmid DNA Covid-19 vaccine ZyCoV-D.
The latter is the first Covid-19 vaccine approved in India for adolescents in the 12-18 years age group.
The management expects to start supplying the vaccine in India from October 2021.
Based on our conservative estimates, we expect Cadila Healthcare to ramp-up production to ~40 million doses from October-21.
We expect a 75:25 split between the government and private channel and a blended price of ~Rs 320/dose for FY22.
Click on the attachment to read the full report:
This report is authored by an external party. BloombergQuint does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BloombergQuint.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.